JP2024512895A5 - - Google Patents
Info
- Publication number
- JP2024512895A5 JP2024512895A5 JP2023553081A JP2023553081A JP2024512895A5 JP 2024512895 A5 JP2024512895 A5 JP 2024512895A5 JP 2023553081 A JP2023553081 A JP 2023553081A JP 2023553081 A JP2023553081 A JP 2023553081A JP 2024512895 A5 JP2024512895 A5 JP 2024512895A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- cysteine
- exendin
- absent
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2021-0046648 | 2021-04-09 | ||
| KR20210046648 | 2021-04-09 | ||
| PCT/KR2022/005188 WO2022216129A1 (ko) | 2021-04-09 | 2022-04-11 | 글루카곤 유도체를 포함하는 만성 신장 질환 예방 또는 치료용 약학 조성물 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024512895A JP2024512895A (ja) | 2024-03-21 |
| JP2024512895A5 true JP2024512895A5 (https=) | 2025-04-21 |
Family
ID=83546549
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023553081A Pending JP2024512895A (ja) | 2021-04-09 | 2022-04-11 | グルカゴン誘導体を含む慢性腎臓疾患予防又は治療用薬学組成物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240197834A1 (https=) |
| EP (1) | EP4321170A4 (https=) |
| JP (1) | JP2024512895A (https=) |
| KR (1) | KR20220140443A (https=) |
| CN (1) | CN117157094A (https=) |
| AU (1) | AU2022254588A1 (https=) |
| BR (1) | BR112023019917A2 (https=) |
| CA (1) | CA3209923A1 (https=) |
| IL (1) | IL305549A (https=) |
| MX (1) | MX2023011759A (https=) |
| WO (1) | WO2022216129A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240124224A (ko) * | 2023-02-07 | 2024-08-16 | (주) 캠프테라퓨틱스 | 미토콘드리아 특이적 펩타이드를 포함하는 신장 또는 간 질환의 예방 또는 치료용 조성물 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| JP4046354B2 (ja) | 1996-03-18 | 2008-02-13 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 増大した半減期を有する免疫グロブリン様ドメイン |
| RU2428430C2 (ru) | 2005-08-16 | 2011-09-10 | Ханми Холдингс Ко., Лтд. | СПОСОБ МАССОВОГО ПРОИЗВОДСТВА ОБЛАСТИ Fc ИММУНОГЛОБУЛИНА С УДАЛЕННЫМИ НАЧАЛЬНЫМИ МЕТИОНИНОВЫМИ ОСТАТКАМИ |
| JP2009534423A (ja) * | 2006-04-20 | 2009-09-24 | アムジェン インコーポレイテッド | Ｇｌｐ−１化合物 |
| JP2008169195A (ja) * | 2007-01-05 | 2008-07-24 | Hanmi Pharmaceutical Co Ltd | キャリア物質を用いたインスリン分泌ペプチド薬物結合体 |
| US8703701B2 (en) * | 2009-12-18 | 2014-04-22 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
| KR101382593B1 (ko) * | 2010-07-21 | 2014-04-10 | 한미사이언스 주식회사 | 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물 |
| CN104583232B (zh) * | 2012-06-21 | 2018-04-13 | 印第安纳大学研究及科技有限公司 | 展现gip受体活性的胰高血糖素类似物 |
| AR092862A1 (es) * | 2012-07-25 | 2015-05-06 | Hanmi Pharm Ind Co Ltd | Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion |
| AR096891A1 (es) | 2013-07-12 | 2016-02-03 | Hanmi Pharm Ind Co Ltd | Conjugado de monómero polipéptido biológicamente activo y conjugado de fragmento fc de inmunoglobulina, que muestra aclaramiento mediado por receptor reducido, y el método para la preparación del mismo |
| PE20171154A1 (es) | 2014-12-30 | 2017-08-16 | Hanmi Pharm Ind Co Ltd | Derivados de glucagon con estabilidad mejorada |
| EP4523705A3 (en) * | 2015-06-30 | 2025-06-11 | Hanmi Pharm. Co., Ltd. | Glucagon derivative and a composition comprising a long acting conjugate of the same |
| EP3479841A4 (en) * | 2016-06-29 | 2020-03-04 | Hanmi Pharm. Co., Ltd. | GLUCAGON DERIVATIVE, CONJUGATE THEREOF, COMPOSITION THEREOF AND THERAPEUTIC USE THEREOF |
| CA3065295C (en) * | 2017-06-01 | 2023-08-29 | Eli Lilly And Company | Dulaglutide for the treatment of chronic kidney disease |
| WO2019140024A1 (en) * | 2018-01-12 | 2019-07-18 | Eli Lilly And Company | Combination therapy |
| WO2020071865A1 (ko) * | 2018-10-04 | 2020-04-09 | 한미약품 주식회사 | 글루카곤 및 이를 포함하는 조합물의 치료학적 용도 |
| KR20210040818A (ko) * | 2019-10-04 | 2021-04-14 | 한미약품 주식회사 | 글루카곤, 및 glp-1 수용체 및 gip 수용체 이중 작용제를 포함하는 조성물 및 이의 치료학적 용도 |
-
2022
- 2022-04-11 CN CN202280027283.1A patent/CN117157094A/zh active Pending
- 2022-04-11 KR KR1020220044574A patent/KR20220140443A/ko active Pending
- 2022-04-11 MX MX2023011759A patent/MX2023011759A/es unknown
- 2022-04-11 BR BR112023019917A patent/BR112023019917A2/pt unknown
- 2022-04-11 US US18/285,753 patent/US20240197834A1/en active Pending
- 2022-04-11 WO PCT/KR2022/005188 patent/WO2022216129A1/ko not_active Ceased
- 2022-04-11 AU AU2022254588A patent/AU2022254588A1/en active Pending
- 2022-04-11 EP EP22785037.7A patent/EP4321170A4/en active Pending
- 2022-04-11 CA CA3209923A patent/CA3209923A1/en active Pending
- 2022-04-11 JP JP2023553081A patent/JP2024512895A/ja active Pending
- 2022-04-11 IL IL305549A patent/IL305549A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230220034A1 (en) | Method for improving solubility of protein and peptide by using immunoglogulin fc fragment linkage | |
| JP6345216B2 (ja) | オキシントモジュリンと免疫グロブリン断片とを含む結合体及びその用途 | |
| JP2022551282A5 (https=) | ||
| AU2009280021B2 (en) | Analogues of glucose-dependent insulinotropic polypeptide (GIP) modified at N-terminal | |
| CN104945500B (zh) | 基于gip的混合激动剂用于治疗代谢紊乱和肥胖症 | |
| JP2019524675A5 (https=) | ||
| JP2020079301A (ja) | オキシントモジュリン誘導体を含む糖尿病又は肥満性糖尿病の治療用組成物 | |
| JP2018526333A5 (https=) | ||
| IL268702A (en) | Use of a dual-acting GLP-1 / glucagon receptor dual agonist for the treatment of non-alcoholic fatty liver disease | |
| CN108025041A (zh) | 胰高血糖素衍生物和包含其长效缀合物的组合物 | |
| WO2014140222A1 (en) | Pegylated glucagon and glp-1 co-agonists for the treatment of obesity | |
| CN116635402B (zh) | 用于代谢病症的融合多肽 | |
| JP2024512895A5 (https=) | ||
| AU2022222674A1 (en) | Glucagon-like peptide-1 receptor antagonists | |
| AU2019405389B2 (en) | Pharmaceutical composition containing insulin and glucagon | |
| JP2022514835A5 (https=) | ||
| CN117157094A (zh) | 包括胰高血糖素衍生物的用于预防或治疗慢性肾病的药物组合物 | |
| JP2025513345A5 (https=) | ||
| RU2021116078A (ru) | Фармацевтическая композиция, содержащая инсулин и глюкагон | |
| HK40052306A (en) | Composition for improving the solubility of a protein or peptide by using immunoglobulin fc fragment linkage | |
| JPWO2022265091A5 (https=) | ||
| WO2024213022A1 (zh) | 肠促胰素类似物及其制备方法和应用 | |
| BR112016022844B1 (pt) | Método e composição para aperfeiçoar a solubilidade de proteína e peptídeo em solução aquosa que compreende um fragmento fc de imunoglobulina | |
| RU2021109760A (ru) | Терапевтическое использование глюкагона и его комбинации | |
| EA040489B1 (ru) | Способ улучшения растворимости белка и пептида за счет использования связывания с фрагментом fc иммуноглобулина |